HH Biotechnology Holdings Company
HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics. The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016. HH Biotechnology Holdings Company was incorpora… Read more
HH Biotechnology Holdings Company (HHBT) - Total Liabilities
Latest total liabilities as of September 2016: $13.15 Million USD
Based on the latest financial reports, HH Biotechnology Holdings Company (HHBT) has total liabilities worth $13.15 Million USD as of September 2016.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HH Biotechnology Holdings Company - Total Liabilities Trend (2012–2015)
This chart illustrates how HH Biotechnology Holdings Company's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
HH Biotechnology Holdings Company Competitors by Total Liabilities
The table below lists competitors of HH Biotechnology Holdings Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EGUVF
PINK:EGUVF
|
USA | $11.69 Million |
|
Universal Media Group Inc
PINK:UMGP
|
USA | $3.34 Million |
|
Fashion Bel Air S.A
PA:ALFBA
|
France | €5.19 Million |
|
BAKRIE SUMATERA PL
BE:OSW
|
Germany | €11.26 Trillion |
|
Hoshi Resource Corp.
V:HRC-P
|
Canada | CA$9.16K |
|
BlackRock American Income Trust Ord
LSE:BRAI
|
UK | GBX3.26 Million |
|
JPMORGAN EMERGING EUROPE MIDDLE EAST & AFRICA SECURITIES PLCc
LSE:JEMA
|
UK | GBX400.00K |
Liability Composition Analysis (2012–2015)
This chart breaks down HH Biotechnology Holdings Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HH Biotechnology Holdings Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HH Biotechnology Holdings Company (2012–2015)
The table below shows the annual total liabilities of HH Biotechnology Holdings Company from 2012 to 2015.
| Year | Total Liabilities | Change |
|---|---|---|
| 2015-12-31 | $18.10 Million | -48.05% |
| 2014-12-31 | $34.85 Million | -1.96% |
| 2013-12-31 | $35.54 Million | +3.58% |
| 2012-12-31 | $34.31 Million | -- |